palmidrol has been researched along with Disease Models, Animal in 82 studies
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the antimitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations such as social withdrawal and cognitive impairment in the social interaction test and in the novel object recognition test, respectively." | 7.91 | Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. ( Babinska, Z; Bari, M; D'Addario, C; Di Bartolomeo, M; Di Marco, R; Di Marzo, V; Drago, F; Drazanova, E; Giurdanella, G; Iannotti, FA; Maccarrone, M; Mechoulam, R; Micale, V; Pekarik, V; Piscitelli, F; Ruda-Kucerova, J; Salomone, S; Starcuk, Z; Stark, T; Sulcova, A; Wotjak, CT, 2019) |
| "The antidepressant effect of a compound formed by co-ultramicronized palmitoylethanolamide (PEA) and luteolin (PEA+luteolin) was investigated in a mouse model of anxiety/depressive-like behavior." | 7.79 | Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression. ( Ahmad, A; Campolo, M; Crupi, R; Cuzzocrea, S; Esposito, E; Paterniti, I, 2013) |
| " The antiinflammatory activity of synthetic cannabinoid nabilone in the rat model of carrageenan-induced acute hindpaw inflammation was compared with that of the endocannabinoid palmitoylethanolamide and the nonsteroidal antiinflammatory drug indomethacin." | 7.71 | Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. ( Colleoni, M; Conti, S; Costa, B; Giagnoni, G; Parolaro, D, 2002) |
| "In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the antimitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations such as social withdrawal and cognitive impairment in the social interaction test and in the novel object recognition test, respectively." | 3.91 | Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. ( Babinska, Z; Bari, M; D'Addario, C; Di Bartolomeo, M; Di Marco, R; Di Marzo, V; Drago, F; Drazanova, E; Giurdanella, G; Iannotti, FA; Maccarrone, M; Mechoulam, R; Micale, V; Pekarik, V; Piscitelli, F; Ruda-Kucerova, J; Salomone, S; Starcuk, Z; Stark, T; Sulcova, A; Wotjak, CT, 2019) |
| " Intraplantar injection of CAR led to a time-dependent development of peripheral inflammation, in terms of paw edema, cytokine release in paw exudates, nitrotyrosine formation, inducible nitric oxide synthase and cyclooxygenase-2 expression." | 3.83 | A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation. ( Bruschetta, G; Cordaro, M; Crupi, R; Cuzzocrea, S; Esposito, E; Gugliandolo, E; Impellizzeri, D; Siracusa, R, 2016) |
| "The antidepressant effect of a compound formed by co-ultramicronized palmitoylethanolamide (PEA) and luteolin (PEA+luteolin) was investigated in a mouse model of anxiety/depressive-like behavior." | 3.79 | Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression. ( Ahmad, A; Campolo, M; Crupi, R; Cuzzocrea, S; Esposito, E; Paterniti, I, 2013) |
| " The antiinflammatory activity of synthetic cannabinoid nabilone in the rat model of carrageenan-induced acute hindpaw inflammation was compared with that of the endocannabinoid palmitoylethanolamide and the nonsteroidal antiinflammatory drug indomethacin." | 3.71 | Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. ( Colleoni, M; Conti, S; Costa, B; Giagnoni, G; Parolaro, D, 2002) |
| "Inflammation is fundamentally a protective cellular response aimed at removing injurious stimuli and initiating the healing process." | 2.52 | N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution. ( Barbierato, M; Bruschetta, G; Cuzzocrea, S; Facci, L; Giusti, P; Impellizzeri, D; Skaper, SD; Zusso, M, 2015) |
| " Clinical trials are now required, but are hindered by a paucity of cannabinoids of suitable bioavailability and therapeutic ratio." | 2.41 | Cannabinoids and pain. ( Rice, AS, 2001) |
| "In rMC-1 cells, PEA suppressed Müller gliosis, reduced inflammatory cytokines, and attenuated profibrotic changes." | 1.56 | PPARα-Dependent Effects of Palmitoylethanolamide Against Retinal Neovascularization and Fibrosis. ( Chen, Q; Huang, C; Jiang, N; Li, J; Liang, X; Liu, Z; Ma, JX; Qiu, Y; Ye, S; Zong, R, 2020) |
| "In an aging society, Alzheimer's disease (AD) exerts an increasingly serious health and economic burden." | 1.48 | Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective effects. ( Bellanti, F; Broad, KD; Bronzuoli, MR; Canese, R; Carpinelli, G; Cassano, T; Facchinetti, R; Ferraro, L; Gaetani, S; Pace, L; Palombelli, G; Scuderi, C; Serviddio, G; Steardo, L, 2018) |
| "Diarrhea is a severe complication in HIV-1-infected patients with Trans-activator of transcription (HIV-1 Tat) protein being recognized as a major underlying cause." | 1.48 | HIV-1 Tat-induced diarrhea is improved by the PPARalpha agonist, palmitoylethanolamide, by suppressing the activation of enteric glia. ( Bruzzese, E; Cuomo, R; D'Alessandro, A; Esposito, G; Gigli, S; Lattanzi, R; Lu, J; Pesce, M; Sarnelli, G; Seguella, L; Steardo, L, 2018) |
| "Idiopathic pulmonary fibrosis was induced in male mice by a single intratracheal administration of saline with bleomycin sulphate (1mg/kg body weight) in a volume of 100μL." | 1.43 | Ultramicronized palmitoylethanolamide (PEA-um(®)) in the treatment of idiopathic pulmonary fibrosis. ( Cordaro, M; Crupi, R; Cuzzocrea, S; Di Paola, R; Esposito, E; Fusco, R; Impellizzeri, D; Siracusa, R, 2016) |
| "Colitis was induced in mice by intracolonic administration of dinitrobenzenesulfonic acid (DNBS)." | 1.42 | Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. ( Battista, G; Borrelli, F; Capasso, R; Coppola, D; Di Marzo, V; Izzo, AA; Orlando, P; Pagano, E; Petrosino, S; Romano, B, 2015) |
| "Cystitis was induced by cyclophosphamide in female rats." | 1.42 | Protective effect of palmitoylethanolamide in a rat model of cystitis. ( Aveta, T; Borrelli, F; Buono, L; Capasso, R; Di Marzo, V; Fiorenzani, P; Izzo, AA; Orlando, P; Pessina, F; Valacchi, G, 2015) |
| "The exposure to Aβ₄₂ induced toxic effects on cultured cortical neurons and astrocytes from non-Tg mice, but not in those from 3xTg-AD mice." | 1.42 | Differential Effects of Palmitoylethanolamide against Amyloid-β Induced Toxicity in Cortical Neuronal and Astrocytic Primary Cultures from Wild-Type and 3xTg-AD Mice. ( Antonelli, T; Beggiato, S; Borelli, AC; Cassano, T; Ferraro, L; Tanganelli, S; Tomasini, MC, 2015) |
| "Anandamide (AEA) is an endocannabinoid (EC) that modulates multiple functions in the CNS and that is released in areas of injury, exerting putative neuroprotective actions." | 1.42 | Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: In vivo studies. ( Cravatt, BF; Hillard, CJ; Koester, EC; Moreno, M; Pazos, MR; Romero, J; Tolón, RM; Vázquez, C, 2015) |
| "Neurotoxicity is a main side effect of the anticancer drug oxaliplatin." | 1.42 | Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity. ( Boccella, S; Calignano, A; Corti, F; Cuzzocrea, S; Di Cesare Mannelli, L; Esposito, E; Ghelardini, C; Luongo, L; Maione, S; Pacini, A, 2015) |
| "Latency to induce seizure, seizure stages and latency and duration of fifth stage of seizure was recorded for each animal." | 1.42 | Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors. ( Aghaei, I; Babaei, P; Khakpour-Taleghani, B; Motamedi, F; Naderi, N; Rostampour, M; Shabani, M, 2015) |
| " The lipidic nature and large particle size of PEA in the native state may limit its solubility and bioavailability when given orally, however." | 1.40 | Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. ( Bruschetta, G; Cordaro, M; Crupi, R; Cuzzocrea, S; Esposito, E; Impellizzeri, D; Siracusa, R, 2014) |
| "To induce hyperalgesia, rat paws were treated with intraplantar prostaglandin E2 (PGE2, 2μg)." | 1.39 | Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors. ( Duarte, ID; Pacheco, Dda F; Romero, TR, 2013) |
| " In addition, the dosage of nitrite in the homogenized paw, as determined by colorimetric assay, indicated that exogenous PEA is able to induce NO release." | 1.38 | Involvement of the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway in peripheral antinociception induced by N-palmitoyl-ethanolamine in rats. ( Cortes, SF; Duarte, ID; Galdino, GS; Perez, AC; Resende, LC; Romero, TR; Silva, GC, 2012) |
| "PEA failed to rescue memory deficits induced by Ab25-35 injection in peroxisome proliferator-activated receptor-α (PPAR-α) null mice." | 1.38 | Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. ( Avagliano, C; Calignano, A; Cristiano, C; D'Agostino, G; Meli, R; Russo, R, 2012) |
| "flank injection of B16 melanoma cells." | 1.38 | The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action. ( Bouzin, C; Feron, O; Gallez, B; Hamtiaux, L; Lambert, DM; Masquelier, J; Muccioli, GG, 2012) |
| "Effects of pre-treatment with a single dose, versus 4 day repeated dosing with the selective FAAH inhibitor, URB597 (i." | 1.38 | Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. ( Alexander, SP; Barrett, DA; Bennett, AJ; Burston, J; Chapman, V; Kendall, DA; Norris, LM; Okine, BN; Patel, A; Woodhams, S, 2012) |
| "Treatment of the middle cerebral artery occlusion (MCAo)-induced animals with PEA reduced edema and brain infractions as evidenced by decreased 2,3,5-triphenyltetrazolium chloride (TTC) staining across brain sections." | 1.38 | Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats. ( Ahmad, A; Crupi, R; Cuzzocrea, S; Esposito, E; Genovese, T; Impellizzeri, D; Marino, A; Velardi, E, 2012) |
| "Spinal cord trauma was induced in mice by the application of vascular clips to the dura via a four-level T5-T8 laminectomy." | 1.37 | Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. ( Cuzzocrea, S; Di Paola, R; Esposito, E; Galuppo, M; Genovese, T; Mazzon, E; Paterniti, I, 2011) |
| "Granuloma was induced by subcutaneous lambda-carrageenin-soaked sponge implants on the back of male Wistar rats." | 1.36 | Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. ( Cipriano, M; D'Amico, A; De Filippis, D; Di Marzo, V; Iuvone, T; Orlando, P; Petrosino, S, 2010) |
| "Inflammatory hyperalgesia was measured following intraplantar injection of carrageenan." | 1.35 | Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. ( Alexander, SP; Barrett, DA; Bennett, AJ; Chapman, V; Garle, MJ; Jhaveri, MD; Kendall, DA; Patel, A; Richardson, D; Robinson, I; Sagar, DR; Sun, Y, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (12.20) | 29.6817 |
| 2010's | 60 (73.17) | 24.3611 |
| 2020's | 12 (14.63) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Li, Y | 2 |
| Zhou, P | 1 |
| Hu, T | 1 |
| Ren, J | 1 |
| Xu, Y | 1 |
| Qiu, Y | 2 |
| Lu, C | 1 |
| D'Amico, R | 2 |
| Monaco, F | 1 |
| Siracusa, R | 10 |
| Cordaro, M | 10 |
| Fusco, R | 5 |
| Peritore, AF | 2 |
| Gugliandolo, E | 4 |
| Crupi, R | 13 |
| Cuzzocrea, S | 22 |
| Di Paola, R | 10 |
| Impellizzeri, D | 16 |
| Genovese, T | 3 |
| Ye, S | 1 |
| Chen, Q | 1 |
| Jiang, N | 1 |
| Liang, X | 1 |
| Li, J | 1 |
| Zong, R | 1 |
| Huang, C | 1 |
| Ma, JX | 1 |
| Liu, Z | 1 |
| Kiso, T | 1 |
| Watabiki, T | 1 |
| Sekizawa, T | 1 |
| Beggiato, S | 2 |
| Cassano, T | 4 |
| Ferraro, L | 3 |
| Tomasini, MC | 2 |
| Hernandez, S | 1 |
| Morales-Soto, W | 1 |
| Grubišić, V | 1 |
| Fried, D | 1 |
| Gulbransen, BD | 1 |
| Sarnelli, G | 4 |
| Pesce, M | 4 |
| Seguella, L | 4 |
| Lu, J | 3 |
| Efficie, E | 1 |
| Tack, J | 1 |
| Elisa De Palma, FD | 1 |
| D'Alessandro, A | 3 |
| Esposito, G | 5 |
| Ardizzone, A | 2 |
| Casili, G | 2 |
| Lanza, M | 1 |
| Esposito, E | 19 |
| Mabou Tagne, A | 1 |
| Fotio, Y | 1 |
| Lin, L | 1 |
| Squire, E | 1 |
| Ahmed, F | 1 |
| Rashid, TI | 1 |
| Karimian Azari, E | 1 |
| Piomelli, D | 3 |
| Corpetti, C | 1 |
| Del Re, A | 1 |
| De Palma, FDE | 1 |
| Sanseverino, W | 1 |
| Campolo, M | 3 |
| Cardali, SM | 1 |
| Scuderi, SA | 1 |
| Conti, A | 1 |
| Inferrera, A | 1 |
| Sasso, O | 1 |
| Summa, M | 2 |
| Armirotti, A | 2 |
| Pontis, S | 2 |
| De Mei, C | 1 |
| Scuderi, C | 4 |
| Bronzuoli, MR | 3 |
| Facchinetti, R | 2 |
| Pace, L | 1 |
| Broad, KD | 1 |
| Serviddio, G | 1 |
| Bellanti, F | 1 |
| Palombelli, G | 1 |
| Carpinelli, G | 1 |
| Canese, R | 1 |
| Gaetani, S | 1 |
| Steardo, L | 9 |
| Gigli, S | 2 |
| Bruzzese, E | 1 |
| Lattanzi, R | 1 |
| Cuomo, R | 2 |
| Romano, A | 1 |
| Stecca, C | 2 |
| Passarella, S | 1 |
| Holubiec, MI | 1 |
| Romero, JI | 1 |
| Suárez, J | 1 |
| Portavella, M | 1 |
| Fernández-Espejo, E | 1 |
| Blanco, E | 1 |
| Galeano, P | 1 |
| de Fonseca, FR | 1 |
| Cristiano, C | 3 |
| Pirozzi, C | 2 |
| Coretti, L | 1 |
| Cavaliere, G | 1 |
| Lama, A | 2 |
| Russo, R | 4 |
| Lembo, F | 1 |
| Mollica, MP | 1 |
| Meli, R | 4 |
| Calignano, A | 5 |
| Mattace Raso, G | 3 |
| Rinne, P | 1 |
| Guillamat-Prats, R | 1 |
| Rami, M | 1 |
| Bindila, L | 1 |
| Ring, L | 1 |
| Lyytikäinen, LP | 1 |
| Raitoharju, E | 1 |
| Oksala, N | 1 |
| Lehtimäki, T | 1 |
| Weber, C | 1 |
| van der Vorst, EPC | 1 |
| Steffens, S | 2 |
| Aldossary, SA | 1 |
| Alsalem, M | 1 |
| Kalbouneh, H | 1 |
| Haddad, M | 1 |
| Azab, B | 1 |
| Al-Shboul, O | 1 |
| Mustafa, AG | 1 |
| Obiedat, S | 1 |
| El-Salem, K | 1 |
| Stark, T | 1 |
| Ruda-Kucerova, J | 1 |
| Iannotti, FA | 1 |
| D'Addario, C | 1 |
| Di Marco, R | 1 |
| Pekarik, V | 1 |
| Drazanova, E | 1 |
| Piscitelli, F | 1 |
| Bari, M | 1 |
| Babinska, Z | 1 |
| Giurdanella, G | 1 |
| Di Bartolomeo, M | 1 |
| Salomone, S | 1 |
| Sulcova, A | 1 |
| Maccarrone, M | 1 |
| Wotjak, CT | 1 |
| Starcuk, Z | 1 |
| Drago, F | 1 |
| Mechoulam, R | 1 |
| Di Marzo, V | 9 |
| Micale, V | 1 |
| Locci, A | 1 |
| Pinna, G | 1 |
| Boccella, S | 2 |
| Marabese, I | 1 |
| Iannotta, M | 1 |
| Belardo, C | 1 |
| Neugebauer, V | 1 |
| Mazzitelli, M | 1 |
| Pieretti, G | 1 |
| Maione, S | 2 |
| Palazzo, E | 1 |
| Evangelista, M | 1 |
| Paterniti, I | 5 |
| Ahmad, A | 6 |
| Capasso, R | 3 |
| Orlando, P | 4 |
| Pagano, E | 2 |
| Aveta, T | 2 |
| Buono, L | 2 |
| Borrelli, F | 3 |
| Izzo, AA | 3 |
| Redlich, S | 1 |
| Ribes, S | 1 |
| Schütze, S | 1 |
| Nau, R | 1 |
| Bruschetta, G | 8 |
| Romano, B | 1 |
| Petrosino, S | 6 |
| Coppola, D | 1 |
| Battista, G | 1 |
| Valenza, M | 1 |
| Ratano, P | 1 |
| Bartoli, S | 1 |
| Pompili, E | 1 |
| Fumagalli, L | 1 |
| Campolongo, P | 1 |
| Khasabova, IA | 1 |
| Yao, X | 1 |
| Paz, J | 1 |
| Lewandowski, CT | 1 |
| Lindberg, AE | 1 |
| Coicou, L | 1 |
| Burlakova, N | 1 |
| Simone, DA | 1 |
| Seybold, VS | 1 |
| Alhouayek, M | 1 |
| Bottemanne, P | 1 |
| Subramanian, KV | 1 |
| Lambert, DM | 3 |
| Makriyannis, A | 2 |
| Cani, PD | 1 |
| Muccioli, GG | 2 |
| Marcolongo, G | 1 |
| Allarà, M | 1 |
| Verde, R | 1 |
| Pessina, F | 1 |
| Valacchi, G | 1 |
| Fiorenzani, P | 1 |
| Sayd, A | 1 |
| Antón, M | 1 |
| Alén, F | 1 |
| Caso, JR | 1 |
| Pavón, J | 1 |
| Leza, JC | 1 |
| Rodríguez de Fonseca, F | 1 |
| García-Bueno, B | 1 |
| Orio, L | 1 |
| Borelli, AC | 1 |
| Tanganelli, S | 1 |
| Antonelli, T | 1 |
| Piras, A | 1 |
| Carta, G | 1 |
| Murru, E | 1 |
| Lopes, PA | 1 |
| Martins, SV | 1 |
| Prates, JA | 1 |
| Banni, S | 1 |
| Vázquez, C | 1 |
| Tolón, RM | 1 |
| Pazos, MR | 1 |
| Moreno, M | 1 |
| Koester, EC | 1 |
| Cravatt, BF | 1 |
| Hillard, CJ | 1 |
| Romero, J | 1 |
| d'Emmanuele di Villa Bianca, R | 1 |
| Simeoli, R | 1 |
| Santoro, A | 1 |
| Di Guida, F | 1 |
| De Caro, C | 2 |
| Sorrentino, R | 1 |
| Iuvone, T | 3 |
| Affaitati, G | 1 |
| De Filippis, D | 2 |
| Lopopolo, M | 1 |
| Grassia, G | 1 |
| Lapenna, D | 1 |
| Negro, L | 1 |
| Costantini, R | 1 |
| Vaia, M | 1 |
| Cipollone, F | 1 |
| Ialenti, A | 1 |
| Giamberardino, MA | 1 |
| Prosdocimi, M | 1 |
| Di Cesare Mannelli, L | 1 |
| Pacini, A | 1 |
| Corti, F | 1 |
| Luongo, L | 1 |
| Ghelardini, C | 1 |
| Skaper, SD | 1 |
| Facci, L | 1 |
| Barbierato, M | 1 |
| Zusso, M | 1 |
| Giusti, P | 1 |
| Aghaei, I | 1 |
| Rostampour, M | 1 |
| Shabani, M | 1 |
| Naderi, N | 1 |
| Motamedi, F | 1 |
| Babaei, P | 1 |
| Khakpour-Taleghani, B | 1 |
| Caltagirone, C | 1 |
| Cisari, C | 1 |
| Schievano, C | 1 |
| Capoccia, E | 1 |
| Nobile, N | 1 |
| Aprea, G | 1 |
| Maione, F | 1 |
| de Palma, GD | 1 |
| Migliore, M | 1 |
| Fuentes de Arriba, AL | 1 |
| Realini, N | 1 |
| Torrente, E | 1 |
| Romeo, E | 1 |
| Di Martino, S | 1 |
| Russo, D | 1 |
| Pizzirani, D | 1 |
| Lanfranco, M | 1 |
| Ottonello, G | 1 |
| Busquet, P | 1 |
| Jung, KM | 1 |
| Garcia-Guzman, M | 1 |
| Heim, R | 1 |
| Scarpelli, R | 1 |
| Avagliano, C | 2 |
| La Rana, G | 1 |
| Piegari, G | 1 |
| Paciello, O | 1 |
| Citraro, R | 1 |
| Russo, E | 1 |
| De Sarro, G | 1 |
| Okine, BN | 2 |
| Madasu, MK | 1 |
| McGowan, F | 1 |
| Prendergast, C | 1 |
| Gaspar, JC | 1 |
| Harhen, B | 1 |
| Roche, M | 1 |
| Finn, DP | 1 |
| Bertolino, B | 1 |
| Jhaveri, MD | 1 |
| Richardson, D | 2 |
| Robinson, I | 1 |
| Garle, MJ | 1 |
| Patel, A | 2 |
| Sun, Y | 1 |
| Sagar, DR | 1 |
| Bennett, AJ | 2 |
| Alexander, SP | 3 |
| Kendall, DA | 2 |
| Barrett, DA | 2 |
| Chapman, V | 3 |
| Loría, F | 1 |
| Mestre, L | 1 |
| Spagnolo, A | 1 |
| Correa, F | 1 |
| Hernangómez, M | 1 |
| Guaza, C | 1 |
| Docagne, F | 1 |
| Karbarz, MJ | 1 |
| Luo, L | 1 |
| Chang, L | 1 |
| Tham, CS | 1 |
| Palmer, JA | 1 |
| Wilson, SJ | 1 |
| Wennerholm, ML | 1 |
| Brown, SM | 1 |
| Scott, BP | 1 |
| Apodaca, RL | 1 |
| Keith, JM | 1 |
| Wu, J | 1 |
| Breitenbucher, JG | 1 |
| Chaplan, SR | 1 |
| Webb, M | 1 |
| Guasti, L | 1 |
| Jhaveri, M | 1 |
| Eldeeb, K | 1 |
| Barrett, D | 1 |
| Elphick, MR | 1 |
| Kendall, D | 1 |
| Michael, GJ | 1 |
| D'Amico, A | 1 |
| Cipriano, M | 1 |
| Johnston, TH | 1 |
| Huot, P | 1 |
| Fox, SH | 1 |
| Wakefield, JD | 1 |
| Sykes, KA | 1 |
| Bartolini, WP | 1 |
| Milne, GT | 1 |
| Pearson, JP | 1 |
| Brotchie, JM | 1 |
| Mazzon, E | 3 |
| Galuppo, M | 1 |
| Yu, HL | 1 |
| Deng, XQ | 1 |
| Li, YJ | 1 |
| Li, YC | 1 |
| Quan, ZS | 1 |
| Sun, XY | 1 |
| Romero, TR | 3 |
| Duarte, ID | 3 |
| Galdino, GS | 1 |
| Silva, GC | 1 |
| Resende, LC | 1 |
| Perez, AC | 1 |
| Cortes, SF | 1 |
| D'Agostino, G | 1 |
| Hamtiaux, L | 1 |
| Masquelier, J | 1 |
| Bouzin, C | 1 |
| Feron, O | 1 |
| Gallez, B | 1 |
| Torre, A | 1 |
| Cappellani, A | 1 |
| Faggio, C | 1 |
| Trischitta, F | 1 |
| Norris, LM | 1 |
| Woodhams, S | 1 |
| Burston, J | 1 |
| Marino, A | 2 |
| Velardi, E | 1 |
| Pacheco, Dda F | 1 |
| Lenglet, S | 1 |
| Thomas, A | 1 |
| Soehnlein, O | 1 |
| Montecucco, F | 1 |
| Burger, F | 1 |
| Pelli, G | 1 |
| Galan, K | 1 |
| Cravatt, B | 1 |
| Staub, C | 1 |
| D'Argenio, G | 1 |
| Gianfrani, C | 1 |
| Valenti, M | 1 |
| Scaglione, G | 1 |
| Grandone, I | 1 |
| Nigam, S | 1 |
| Sorrentini, I | 1 |
| Mazzarella, G | 1 |
| Bisogno, T | 2 |
| Martire, A | 1 |
| Popoli, P | 1 |
| Baker, D | 1 |
| Pryce, G | 1 |
| Croxford, JL | 1 |
| Brown, P | 1 |
| Pertwee, RG | 1 |
| Khanolkar, A | 1 |
| Layward, L | 1 |
| Fezza, F | 1 |
| Di Marzo , V | 1 |
| Vandevoorde, S | 1 |
| Diependaele, G | 1 |
| Govaerts, SJ | 1 |
| Robert, AR | 1 |
| Rice, AS | 1 |
| Conti, S | 1 |
| Costa, B | 1 |
| Colleoni, M | 1 |
| Parolaro, D | 1 |
| Giagnoni, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| THE EFFECT OF DIETARY SUPPLEMENTATION WITH PALMITOYLETHANOLAMIDE ON GASTROINTESTINAL SYMPTOMS IN FUNCTIONAL DYSPEPSIA PATIENTS.[NCT05877781] | 100 participants (Anticipated) | Interventional | 2021-11-29 | Recruiting | |||
| Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Postoperative Pain and Inflammation Following Below Knee Fracture Fixation: A Pilot Study.[NCT05317676] | Phase 2 | 0 participants (Actual) | Interventional | 2023-05-31 | Withdrawn (stopped due to Sponsor suspending temporarily.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for palmidrol and Disease Models, Animal
| Article | Year |
|---|---|
N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution.
Topics: Administration, Oral; Amides; Amidohydrolases; Animals; Anti-Inflammatory Agents; Antidepressive Age | 2015 |
Cannabinoids and pain.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Benzoxazines; Brain; Camphanes; Can | 2001 |
80 other studies available for palmidrol and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
NAAA inhibitor F96 attenuates BBB disruption and secondary injury after traumatic brain injury (TBI).
Topics: Amides; Amidohydrolases; Animals; Blood-Brain Barrier; Brain Injuries, Traumatic; Cell Line; Disease | 2021 |
Ultramicronized Palmitoylethanolamide in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation.
Topics: Amides; Animals; Blood Coagulation Disorders; COVID-19; Cytokines; Disease Models, Animal; Dissemina | 2021 |
PPARα-Dependent Effects of Palmitoylethanolamide Against Retinal Neovascularization and Fibrosis.
Topics: Administration, Oral; Amides; Animals; Blotting, Western; Cannabinoid Receptor Agonists; Cell Line; | 2020 |
ASP8477, a fatty acid amide hydrolase inhibitor, exerts analgesic effects in rat models of neuropathic and dysfunctional pain.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Behavior, Animal; Brain; Chronic Pain; Disease Models, | 2020 |
Astrocytic palmitoylethanolamide pre-exposure exerts neuroprotective effects in astrocyte-neuron co-cultures from a triple transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Animals; Astrocytes; Cell Survival; Cerebral Corte | 2020 |
Pyridostigmine bromide exposure creates chronic, underlying neuroimmune disruption in the gastrointestinal tract and brain that alters responses to palmitoylethanolamide in a mouse model of Gulf War Illness.
Topics: Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cholinesterase Inhibitors; Chronic | 2020 |
Impaired Duodenal Palmitoylethanolamide Release Underlies Acid-Induced Mast Cell Activation in Functional Dyspepsia.
Topics: Adult; Amides; Animals; Biopsy; Case-Control Studies; Disease Models, Animal; Duodenum; Dyspepsia; E | 2021 |
Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain.
Topics: Acetylcarnitine; Amides; Animals; Carrageenan; Cell Count; Cyclooxygenase 2; Disease Models, Animal; | 2021 |
Palmitoylethanolamide and hemp oil extract exert synergistic anti-nociceptive effects in mouse models of acute and chronic pain.
Topics: Acute Pain; Amides; Analgesics; Animals; Cannabis; Chronic Pain; Disease Models, Animal; Drug Synerg | 2021 |
Engineered
Topics: Amides; Animals; Colitis; Dextran Sulfate; Disease Models, Animal; Ethanolamines; Humans; Inflammati | 2021 |
Co-Ultra PEALut Enhances Endogenous Repair Response Following Moderate Traumatic Brain Injury.
Topics: Administration, Oral; Adult; Aged; Amides; Animals; Brain Injuries, Traumatic; Disease Models, Anima | 2021 |
Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Amides; Animals; Anti-Inflammatory Agents; Antioxidants; Apop | 2017 |
The N-Acylethanolamine Acid Amidase Inhibitor ARN077 Suppresses Inflammation and Pruritus in a Mouse Model of Allergic Dermatitis.
Topics: Amides; Amidohydrolases; Animals; Carbamates; Dermatitis, Allergic Contact; Dinitrofluorobenzene; Di | 2018 |
Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective effects.
Topics: Age Factors; Alzheimer Disease; Amides; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Be | 2018 |
HIV-1 Tat-induced diarrhea is improved by the PPARalpha agonist, palmitoylethanolamide, by suppressing the activation of enteric glia.
Topics: Amides; Anesthetics, Local; Animals; Antiviral Agents; Diarrhea; Disease Models, Animal; Ethanolamin | 2018 |
Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer's Disease:
Topics: Alzheimer Disease; Amides; Animals; Astrocytes; Disease Models, Animal; Ethanolamines; Gliosis; Huma | 2018 |
Palmitoylethanolamide prevents neuroinflammation, reduces astrogliosis and preserves recognition and spatial memory following induction of neonatal anoxia-ischemia.
Topics: Amides; Animals; Disease Models, Animal; Endocannabinoids; Ethanolamines; Female; Glucose; Hippocamp | 2018 |
Palmitoylethanolamide counteracts autistic-like behaviours in BTBR T+tf/J mice: Contribution of central and peripheral mechanisms.
Topics: Amides; Animals; Autism Spectrum Disorder; Autistic Disorder; Brain; Brain-Derived Neurotrophic Fact | 2018 |
Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation.
Topics: Amides; Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Atherosclerosis; c-Mer Tyrosine K | 2018 |
The role of transient receptor potential vanilloid receptor 1 and peroxisome proliferator-activated receptors-α in mediating the antinociceptive effects of palmitoylethanolamine in rats.
Topics: Amides; Analgesics; Animals; Disease Models, Animal; Ethanolamines; Ganglia, Spinal; Male; Nocicepti | 2019 |
Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia.
Topics: Amides; Animals; Arachidonic Acids; Cannabidiol; Disease Models, Animal; Endocannabinoids; Ethanolam | 2019 |
Stimulation of Peroxisome Proliferator-Activated Receptor-α by N-Palmitoylethanolamine Engages Allopregnanolone Biosynthesis to Modulate Emotional Behavior.
Topics: Amides; Animals; Anxiety; Disease Models, Animal; Emotions; Ethanolamines; Fear; Hippocampus; Male; | 2019 |
Metabotropic Glutamate Receptor 5 and 8 Modulate the Ameliorative Effect of Ultramicronized Palmitoylethanolamide on Cognitive Decline Associated with Neuropathic Pain.
Topics: Amides; Animals; Dentate Gyrus; Disease Models, Animal; Ethanolamines; Excitatory Postsynaptic Poten | 2019 |
The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice.
Topics: Amides; Analgesics; Animals; Anti-Inflammatory Agents; Apoptosis; Cytokines; Diabetic Neuropathies; | 2019 |
Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression.
Topics: Amides; Animals; Antidepressive Agents; Anxiety; Apoptosis; Behavior, Animal; Brain; Brain-Derived N | 2013 |
Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels.
Topics: Amides; Animals; Colitis; Disease Models, Animal; Ethanolamines; Gastrointestinal Motility; Inflamma | 2014 |
Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 by macrophages and increases the resistance of mice against infections.
Topics: Amides; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cells, Cultured; | 2014 |
Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.
Topics: Administration, Oral; Amides; Analgesics; Animals; Carrageenan; Chemistry, Pharmaceutical; Chromatog | 2014 |
Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent.
Topics: Administration, Oral; Amides; Animals; Anti-Inflammatory Agents; Benzenesulfonates; Capsaicin; Colit | 2015 |
Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Amides; Animals; Disease Models, Animal; Ethanolamines; Gliosis; Humans; Male; Ne | 2014 |
JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.
Topics: Amides; Analgesics; Animals; Antineoplastic Agents; Arachidonic Acids; Benzodioxoles; Cells, Culture | 2014 |
N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis.
Topics: Amides; Amidohydrolases; Animals; Anti-Inflammatory Agents; Arachidonic Acids; Chromatography, High | 2015 |
Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Anthraquinones; Anti-Inflammatory Agents; Carrageenan; | 2015 |
Protective effect of palmitoylethanolamide in a rat model of cystitis.
Topics: Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclophosphamide; Cystitis; Disease Models | 2015 |
Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats.
Topics: Amides; Anhedonia; Animals; Anti-Inflammatory Agents; Behavior, Animal; Body Temperature Regulation; | 2014 |
Differential Effects of Palmitoylethanolamide against Amyloid-β Induced Toxicity in Cortical Neuronal and Astrocytic Primary Cultures from Wild-Type and 3xTg-AD Mice.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; | 2015 |
Effects of dietary CLA on n-3 HUFA score and N-acylethanolamides biosynthesis in the liver of obese Zucker rats.
Topics: Amides; Animals; Dietary Supplements; Disease Models, Animal; Docosahexaenoic Acids; Endocannabinoid | 2015 |
Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: In vivo studies.
Topics: Adenosine Triphosphate; Amides; Amidohydrolases; Animals; Anti-Inflammatory Agents; Apyrase; Arachid | 2015 |
The anti-inflammatory effects of palmitoylethanolamide (PEA) on endotoxin-induced uveitis in rats.
Topics: Active Transport, Cell Nucleus; Amides; Animals; Anti-Inflammatory Agents; Dexamethasone; Disease Mo | 2015 |
Palmitoylethanolamide treatment reduces blood pressure in spontaneously hypertensive rats: involvement of cytochrome p450-derived eicosanoids and renin angiotensin system.
Topics: Amides; Animals; Biological Factors; Blood Pressure; Carotid Arteries; Disease Models, Animal; Eicos | 2015 |
Ultramicronized palmitoylethanolamide reduces viscerovisceral hyperalgesia in a rat model of endometriosis plus ureteral calculosis: role of mast cells.
Topics: Amides; Animals; Chymases; Disease Models, Animal; Endometriosis; Ethanolamines; Female; Hyperalgesi | 2016 |
Effects of palmitoylethanolamide and silymarin combination treatment in an animal model of kidney ischemia and reperfusion.
Topics: Active Transport, Cell Nucleus; Amides; Animals; Apoptosis; Cell Nucleus; Chymases; Cytokines; Disea | 2015 |
Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity.
Topics: Activating Transcription Factor 3; Amides; Animals; Behavior, Animal; Disease Models, Animal; Ethano | 2015 |
Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors.
Topics: Amides; Animals; Anticonvulsants; Disease Models, Animal; Ethanolamines; Kindling, Neurologic; Male; | 2015 |
A novel protective formulation of Palmitoylethanolamide in experimental model of contrast agent induced nephropathy.
Topics: Acute-Phase Proteins; Amides; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Ur | 2016 |
Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man.
Topics: Adult; Aged; Aged, 80 and over; Amides; Animals; Antioxidants; Behavior, Animal; Brain Ischemia; Coh | 2016 |
A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation.
Topics: Active Transport, Cell Nucleus; Administration, Oral; Amides; Animals; Carrageenan; Cell Line, Tumor | 2016 |
Palmitoylethanolamide Modulates Inflammation-Associated Vascular Endothelial Growth Factor (VEGF) Signaling via the Akt/mTOR Pathway in a Selective Peroxisome Proliferator-Activated Receptor Alpha (PPAR-α)-Dependent Manner.
Topics: Adult; Amides; Animals; Cells, Cultured; Colitis; Colitis, Ulcerative; Dextran Sulfate; Disease Mode | 2016 |
Ultramicronized palmitoylethanolamide (PEA-um(®)) in the treatment of idiopathic pulmonary fibrosis.
Topics: Amides; Animals; Biomarkers; Bleomycin; Disease Models, Animal; Dose-Response Relationship, Drug; Dr | 2016 |
Second-Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis.
Topics: Administration, Oral; Amides; Amidohydrolases; Animals; Disease Models, Animal; Dose-Response Relati | 2016 |
Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence.
Topics: Amides; Animals; Apoptosis; Cell Death; Cyclooxygenase 2; Disease Models, Animal; Dopamine; Dopamine | 2016 |
N-palmitoylethanolamide in the anterior cingulate cortex attenuates inflammatory pain behaviour indirectly via a CB1 receptor-mediated mechanism.
Topics: Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cannabinoid Receptor Antagonists; Cohort S | 2016 |
Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism.
Topics: Amides; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Autistic Disorder; Brain | 2017 |
Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain.
Topics: Amides; Amidohydrolases; Animals; Benzamides; Cannabinoid Receptor Modulators; Carbamates; Carrageen | 2008 |
Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide.
Topics: Amides; Animals; Anti-Inflammatory Agents; Antiviral Agents; Cannabinoid Receptor Modulators; Cytoki | 2008 |
Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Brain; Carrageenan; Disease Models, | 2009 |
Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain.
Topics: Amides; Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cell Proliferation; Disease Mod | 2009 |
Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats.
Topics: Amides; Amidohydrolases; Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Carrageenan; C | 2010 |
Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.
Topics: Amides; Amidohydrolases; Animals; Benzamides; Callithrix; Carbamates; Disease Models, Animal; Dyskin | 2011 |
Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury.
Topics: Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Astrocytes; Cell Degranulation; Chymases; | 2011 |
N-palmitoylethanolamide, an endocannabinoid, exhibits antidepressant effects in the forced swim test and the tail suspension test in mice.
Topics: Administration, Oral; Amides; Animals; Antidepressive Agents; Cannabinoid Receptor Modulators; Depre | 2011 |
N-palmitoyl-ethanolamine (PEA) induces peripheral antinociceptive effect by ATP-sensitive K+-channel activation.
Topics: Amides; Analgesics; Animals; Dequalinium; Dinoprostone; Disease Models, Animal; Dose-Response Relati | 2012 |
Involvement of the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway in peripheral antinociception induced by N-palmitoyl-ethanolamine in rats.
Topics: Amides; Analgesics; Animals; Arginine; Cyclic GMP; Disease Models, Animal; Endocannabinoids; Ethanol | 2012 |
Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Animals; Disease Models, Animal; Endocannabinoids; | 2012 |
The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action.
Topics: Amides; Animals; Arachidonic Acids; Benzamides; Cannabinoid Receptor Modulators; Carbamates; Cell De | 2012 |
Effects of palmitoylethanolamide on intestinal injury and inflammation caused by ischemia-reperfusion in mice.
Topics: Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; bcl-2-Associated X Protein; Disease Models | 2012 |
Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system.
Topics: Amides; Amidohydrolases; Animals; Arachidonic Acids; Behavior, Animal; Benzamides; Carbamates; Disea | 2012 |
Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice.
Topics: Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Brain Injuries; Disease Models, | 2012 |
Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease.
Topics: Amides; Animals; Astrocytes; bcl-2-Associated X Protein; Behavior, Animal; Catalepsy; Cell Membrane; | 2012 |
Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats.
Topics: Amides; Animals; Astrocytes; Brain Injuries; Disease Models, Animal; Endocannabinoids; Ethanolamines | 2012 |
Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors.
Topics: Amides; Analysis of Variance; Animals; Arachidonic Acids; Calcium Channel Blockers; Cannabinoid Rece | 2013 |
Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice.
Topics: Amides; Amidohydrolases; Animals; Aorta; Aortic Diseases; Apolipoproteins E; Arachidonic Acids; Athe | 2013 |
Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease.
Topics: Alzheimer Disease; Amides; Animals; Cell Survival; Cells, Cultured; Disease Models, Animal; Endocann | 2013 |
Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats.
Topics: Adolescent; Adult; Amides; Animals; Arachidonic Acids; Atrophy; Cannabinoid Receptor Modulators; Cas | 2007 |
Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease.
Topics: Amides; Animals; Brain; Cannabinoid Receptor Modulators; Disease Models, Animal; Endocannabinoids; E | 2008 |
Endocannabinoids control spasticity in a multiple sclerosis model.
Topics: Amides; Animals; Arachidonic Acids; Brain; Cannabinoid Receptor Modulators; Cannabinoids; Disease Mo | 2001 |
Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice.
Topics: Amides; Animals; Anticonvulsants; Cannabinoid Receptor Modulators; Cannabinoids; Convulsants; Diseas | 2001 |
Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat.
Topics: Acute Disease; Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Camphanes; Cannabinoid Rece | 2002 |